<DOC>
	<DOCNO>NCT01284322</DOCNO>
	<brief_summary>The purpose study determine fresolimumab safe treat people systemic sclerosis ( scleroderma ) investigate effect fresolimumab skin individual .</brief_summary>
	<brief_title>Fresolimumab In Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Meet ACR criterion diffuse systemic sclerosis &lt; 24 month since onset first SSc manifestation Raynaud 's phenomenon Modified Rodnan Skin Score ≥ 15 Male female adult ( ≥ 18 year age ) Able willing give write informed consent comply study protocol Moderate severe pulmonary disease w/ FVC &lt; 80 % DLCO &lt; 70 % ground glass fibrosis &gt; 20 % lung field HRCT Treatment investigational drug within 4 week screen Ongoing use high dose steroid ( &gt; 10mg/day ) unstable steroid dose past 4 week Treatment immunosuppressive , cytotoxic , antifibrotic drug within 4 week screen Positive HIV , HBV , and/or HCV Known active infection ( bacterial , viral , fungal , mycobacterial , ) ; include fungal infection nail bed major infection require hospitalization treatment IV antibiotic within 4 week screen Patients w/ history malignancy premalignant lesion History keratoacanthoma squamous cell carcinoma Moderate severe hepatic impairment SSc renal crisis within 6 month creatinine &gt; 2.0 Lack IV access medication administration Moderate severe cardiac disease significant arrhythmia , heart failure , unstable angina Anemia ( Hb &lt; 8.5 gm/dL ) Thrombocytopenia blood clot disorder Patients organ transplant ( include allogeneic bone marrow transplant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>